Day: December 15, 2022

PharmaTher’s 4th FDA orphan drug designation for ketamine TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ketamine in the prevention of ischemia-reperfusion injury from organ transplantation. The Company currently holds four orphan drug designations granted by the FDA for ketamine, which include:Ketamine to prevent ischemia-reperfusion injury from organ transplantation; Ketamine to treat Status Epilepticus, a rare neurological disorder requiring emergency treatment for a seizure; Ketamine to treat Amyotrophic Lateral Sclerosis, a progressive neuromuscular disease with a life expectancy of only two...

Figure 1 Map of Novo’s Pilbara tenureFigure 2 Map of Quartz Hill and the NGPNot for distribution to United States Newswire Services or for dissemination in the United States HIGHLIGHTSLiatam Mining Pty Ltd (“Liatam”), Australian-based manager of the Bald Hill lithium and tantalum mine in Western Australia, will make a strategic investment of C$5 million in Novo (the “Financing”) through the purchase of 12,820,512 units of Novo at C$0.39 per unit (each, a “Unit”), representing an undiluted 4.9% post-Financing position in Novo The Unit price represents a 26% premium to Novo’s closing price on December 14, 2022 and Novo’s 30-day trailing volume-weighted average price (“VWAP”), and the Financing is subject to a contractual hold period expiring June 30, 2023 Each Unit will consist of one common share of Novo and one-quarter of one common...

SAN DIEGO, Dec. 15, 2022 (GLOBE NEWSWIRE) — Salona Global Medical Device Corporation (“Salona Global”, “SGMD”, or the “Company”) (TSXV:SGMD) announced today its intention to focus on listing on the Nasdaq Capital Market (“Nasdaq”) in 2023. As a first step, Salona Global has changed its fiscal year end to December 31, 2022 with the aim of preparing for a U.S. listing, and has withdrawn the recently announced debenture offering in Canada. Salona will move forward with the process of closing the recently announced acquisition of assets of Biodex Medical Systems, Inc. without participation from the Canadian capital markets. “I believe our company has sufficient size, growth and scope to start considering a listing on Nasdaq in the U.S. in 2023,” said Salona Global Executive Chairman Les Cross. “To that end, we have elected to change...

Atlanta, GA, Dec. 15, 2022 (GLOBE NEWSWIRE) — T Stamp Inc. (“Trust Stamp” or the “Company”) (Nasdaq: IDAI), a global provider of AI-powered identity services for use across multiple sectors, today announced the engagement of Marcum, LLP, as the Company’s new independent registered public accounting firm. Alex Valdes, Chief Financial Officer, commented, “Marcum is one of the top-ranked accounting firms for rapidly growing small-cap companies, and runs the fifth largest SEC auditing practice in the U.S.  They have a proven track record with more than 70 years of experience serving middle-market companies in the services and technology industries. With Trust Stamp’s offices located in seven countries across North America, Europe, Asia, and Africa, Marcum’s international capabilities will be invaluable as we continue to grow...

New Collaboration to Increase Payer Reimbursements and Patient Access LITTLETON, Colo., Dec. 15, 2022 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), today announced the creation of a new strategic collaboration with Nexus Dental Systems (“Nexus”), which Vivos expects to generate new revenues starting immediately. Vivos and Nexus believe their alliance is a natural one as both companies currently operate successful independent medical billing platforms focused on sleep and breathing disorders. The agreement between Vivos and Nexus effectively combines Vivos’ proprietary out-of-network Billing Intelligence Service with the Nexus’ in-network medical billing platform to create what is expected to be one of the most comprehensive medical billing services in the dental industry. This collaboration...

TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) — REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) announces that it is expanding its previously announced private placement (see November 30, 2022 press release) to investors resident in the Province of Quebec. The Company is arranging a private placement of a minimum of $3 million and a maximum of $5 million of units (each, a “Unit”) at a price of $0.15 per Unit (the “Offering”). The Offering is being led by EMD Financial Inc. Each Unit shall be comprised of one common share (“Common Share”) in the capital of the Company and one (1) Common Share purchase warrant (“Warrant”) of the Company. Each Warrant shall entitle the holder thereof to acquire one additional Common Share at a price of $0.20 for a period of thirty-six (36) months from the closing date (the...